3B Pharmaceuticals GmbH

ITM and Debiopharm Initiate New Study Arm for CAIX-Targeted Theranostic in Clear Cell Renal Cell Carcinoma

- ITM and Debiopharm announced the first patient imaging in Part D of their Phase 1/2 trial evaluating ITM-94 as a diagnostic agent for clear cell renal cell carcinoma. - The study will assess ITM-94's effectiveness in classifying indeterminate renal masses as cancerous or non-cancerous, enrolling approximately 36 patients across 15 clinical sites. - ITM-94 demonstrated exceptional imaging characteristics in Part A, with high tumor-to-background ratios and ability to detect lesions not visible by CT scan. - The theranostic pair ITM-91/ITM-94 targets CAIX, which is overexpressed in more than 90% of clear cell renal cell carcinoma cases.